Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

ABSTRACT:

Background

Recently, the United States Food and Drug Administration (USFDA) approved viloxazine extended-release (ER) to manage attention-deficit hyperactivity disorder (ADHD) in pediatric patients of 6-17 years of age.

Objective

To perform a meta-analysis to determine the safety and efficacy of viloxazine ER in the management of ADHD.

Data source and methods

A literature search was performed through the databases Cochrane Library, PubMed, and clinicaltrials.gov, for a period from inception to August 2021, with the keywords: viloxazine, SPN-812, ADHD, and randomized clinical trials. The randomized controlled trials published in English language that analyzed the efficacy and safety were included. The risk of bias (RoB) was assessed by RoB tool. The outcomes included i

SUBMITTER: Singh A 

PROVIDER: S-EPMC9125110 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature